The stock of Relmada Therapeutics Inc (RLMD) has seen a -2.60% decrease in the past week, with a -87.42% drop in the past month, and a -89.58% decrease in the past quarter. The volatility ratio for the week is 10.93%, and the volatility levels for the past 30 days are at 13.23% for RLMD. The simple moving average for the past 20 days is -65.41% for RLMD’s stock, with a -88.96% simple moving average for the past 200 days.
Is It Worth Investing in Relmada Therapeutics Inc (NASDAQ: RLMD) Right Now?
The 36-month beta value for RLMD is also noteworthy at 0.45. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RLMD is 25.28M, and at present, short sellers hold a 7.05% of that float. The average trading volume of RLMD on December 26, 2024 was 772.26K shares.
RLMD) stock’s latest price update
The stock of Relmada Therapeutics Inc (NASDAQ: RLMD) has decreased by -4.79 when compared to last closing price of 0.38.Despite this, the company has seen a loss of -2.60% in its stock price over the last five trading days. reuters.com reported 2024-12-09 that Relmada Therapeutics said on Monday it would discontinue the two late-stage studies planned for the development of its depression drug and explore strategic alternatives including a sale.
Analysts’ Opinion of RLMD
Many brokerage firms have already submitted their reports for RLMD stocks, with Mizuho repeating the rating for RLMD by listing it as a “Neutral.” The predicted price for RLMD in the upcoming period, according to Mizuho is $1 based on the research report published on December 05, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see RLMD reach a price target of $13, previously predicting the price at $3.50. The rating they have provided for RLMD stocks is “Buy” according to the report published on September 17th, 2024.
Goldman gave a rating of “Sell” to RLMD, setting the target price at $2 in the report published on June 05th of the current year.
RLMD Trading at -85.01% from the 50-Day Moving Average
After a stumble in the market that brought RLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.00% of loss for the given period.
Volatility was left at 13.23%, however, over the last 30 days, the volatility rate increased by 10.93%, as shares sank -86.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -89.21% lower at present.
During the last 5 trading sessions, RLMD fell by -0.08%, which changed the moving average for the period of 200-days by -93.74% in comparison to the 20-day moving average, which settled at $1.0450. In addition, Relmada Therapeutics Inc saw -91.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLMD starting from TRAVERSA SERGIO, who purchase 51,407 shares at the price of $2.99 back on Sep 11 ’24. After this action, TRAVERSA SERGIO now owns 384,024 shares of Relmada Therapeutics Inc, valued at $153,707 using the latest closing price.
TRAVERSA SERGIO, the Chief Executive Officer of Relmada Therapeutics Inc, purchase 55,579 shares at $2.71 during a trade that took place back on Sep 09 ’24, which means that TRAVERSA SERGIO is holding 299,603 shares at $150,619 based on the most recent closing price.
Stock Fundamentals for RLMD
The total capital return value is set at -1.92. Equity return is now at value -116.60, with -104.91 for asset returns.
Currently, EBITDA for the company is 4.91 million with net debt to EBITDA at 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.89.
Conclusion
In summary, Relmada Therapeutics Inc (RLMD) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
